Thomas Brevig, MD, PhD, HD
机构: Head of Global Clinical Development & Medical Affairs - CNS, Gedeon Richter Plc.
每年引用次数
引用次数
引用: 864
H-指数: 16
I10-指数 : 20
出版物: 72
Direct cytotoxic response of human lymphocytes to porcine PHA-lymphoblasts and lymphocytes.
THOMAS BREVIG , TOM KRISTENSEN
Apmis 105 ( 4) 290 -298
7
1997
REDUCTION OF THE IMMUNOGENICITY OF NON-HUMAN GRAFTS
Thomas BREVIG , Tom KRISTENSEN , Jens ZIMMER RASMUSSEN , Jan HOLGERSSON
2001
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
Egilius L. H. Spierings , Roger Cady , Vivienne Shen , Timothy R. Smith
Journal of Headache and Pain 22 ( 1) 1 -11
1
2021
Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them
Thomas Brevig , Jan Holgersson , Håkan Widner
Trends in Neurosciences 23 ( 8) 337 -344
63
2000
Oxygen reduces accumulation of type IV collagen in endothelial cell subcellular matrix via oxidative stress.
Thomas Brevig , Jette H. Røhrmann , Holger Riemann
Artificial Organs 30 ( 12) 915 -921
6
2006
Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: A qualitative study
Cecilia Brain , Steven Kymes , Dana B. DiBenedetti , Thomas Brevig
BMC Psychiatry 18 ( 1) 253 -253
14
2018
Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists
Christoph U. Correll , Thomas Brevig , Cecilia Brain
BMC Psychiatry 19 ( 1) 362 -362
6
2019
The recognition of adsorbed and denatured proteins of different topographies by β2 integrins and effects on leukocyte adhesion and activation
Thomas Brevig , Bjørn Holst , Zahida Ademovic , Noemi Rozlosnik
Biomaterials 26 ( 16) 3039 -3053
61
2005
Neural xenotransplantation: pretreatment of porcine embryonic nigral tissue with anti-Gal antibodies and complement is not toxic for the dopaminergic neurons.
Thomas Brevig , Morten Meyer , Tom Kristensen , Jens Zimmer
Cell Transplantation 10 ( 1) 25 -30
5
2001
Activated porcine embryonic brain endothelial cells induce a proliferative human T-lymphocyte response.
Suchitra Sumitran-Holgersson , Thomas Brevig , Håkan Widner , Jan Holgersson
Cell Transplantation 12 ( 6) 637 -646
8
2003
Hydrodynamic guiding for addressing subsets of immobilized cells and molecules in microfluidic systems.
Thomas Brevig , Ulrich Krühne , Rachel A Kahn , Thomas Ahl
BMC Biotechnology 3 ( 1) 10 -10
19
2003
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Hans‐Christoph Diener , Michael J. Marmura , Stewart J. Tepper , Robert Cowan
Headache 61 ( 1) 125 -136
1
2021
Molecular and cellular mechanisms in immune rejection of intracerebral neural transplants.
Thomas Brevig , Erik Bo Pedersen , Bente Finsen
Novartis Foundation symposium 231 166 -183
16
2000
Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists.
Christoph U Correll , Thomas Brevig , Cecilia Brain
Neuropsychiatric Disease and Treatment 15 3461 -3473
3
2019
Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain.
Thomas Brevig , Tom Kristensen , Jens Zimmer
Experimental Neurology 159 ( 2) 474 -483
21
1999
Lipid-mediated glial cell line-derived neurotrophic factor gene transfer to cultured porcine ventral mesencephalic tissue.
Matthias Bauer , Morten Meyer , Thomas Brevig , Thomas Gasser
Experimental Neurology 177 ( 1) 40 -49
6
2002
Patient-centered assessment of cognitive symptoms of depression.
Sheri E. Fehnel , Barbara H. Forsyth , Dana B. DiBenedetti , Natalya Danchenko
Cns Spectrums 21 ( 1) 43 -52
32
2016
Risk factors for migraine disease progression: a narrative review for a patient-centered approach
Richard B Lipton , Dawn C Buse , Stephanie J Nahas , Gretchen E Tietjen
Journal of Neurology 270 ( 12) 5692 -5710
15
2023
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
Richard B Lipton , Larry Charleston IV , Cristina Tassorelli , Thomas Brevig
The Journal of Headache and Pain 23 ( 1) 23 -23
4
2022
Patients souffrant de migraine présentant une réduction≥ 75% du nombre de jours mensuels de migraine (répondeurs≥ 75%) avec eptinezumab: analyse en sous-groupes des études PROMISE-1 et PROMISE-2
Richard Lipton , Larry Iv Charleston , Cristina Tassorelli , Thomas Brevig
Revue Neurologique 178 S25 -S26
2022
Amaal Starling Jens Zimmer Zahida Ademovic Peter Kingshott Holst,B Morten Meyer Stewart Tepper Niels B. Larsen Dawn C. Buse hakan widner Christoph Correll; Christoph U Correll Richard B.Lipton, M.D. Dawn I Velligan Kevin Marsh Noemi Rozlosnik Raymond W. Lam, MD, FRCPC, FCAHS Martin Bøg Jessica Ailani Ulrich Krühne